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Background: Chronic conditions are a major source of morbidity, mortality and cost worldwide. Shared decision
making is one way to improve care for patients with chronic conditions. Although it has been widely studied, the
effect of shared decision making in the context of chronic conditions is unknown.
Methods/Design: We will perform a systematic review with the objective of determining the effectiveness of
shared decision making interventions for persons diagnosed with chronic conditions. We will search the following
databases for relevant articles: PubMed, Scopus, Ovid MEDLINE, Ovid EMBASE, Ovid EBM Reviews CENTRAL, CINAHL,
and Ovid PsycInfo. We will also search clinical trial registries and contact experts in the field to identify additional
studies. We will include randomized controlled trials studying shared decision making interventions in patients with
chronic conditions who are facing an actual decision. Shared decision making interventions will be defined as any
intervention aiming to facilitate or improve patient and/or clinician engagement in a decision making process. We
will describe all studies and assess their quality. After adjusting for missing data, we will analyze the effect of shared
decision making interventions on outcomes in chronic conditions overall and stratified by condition. We will
evaluate outcomes according to an importance ranking informed by a variety of stakeholders. We will perform
several exploratory analyses including the effect of author contact on the estimates of effect.
Discussion: We anticipate that this systematic review may have some limitations such as heterogeneity and
imprecision; however, the results will contribute to improving the quality of care for individuals with chronic
conditions and facilitate a process that allows decision making that is most consistent with their own values and
preferences.
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Nearly half of all Americans have at least one chronic
condition [1]. Consequently, chronic conditions account
for 78% of all healthcare costs [2] and are responsible
for 70% of the deaths that occur in America every year
[1]. Worldwide, chronic conditions, such as diabetes,
cardiovascular disease, and cancer, are responsible for
over 36 million deaths every year [3] and a cost of up to
US$23 trillion [4]. In addition to the impact that chronic
conditions have at the public health level, they also im-
pose morbidity at the individual patient level. This mani-
fests as increased suffering and diminished quality of life
for the patient [5], heightened burden on their caregivers
[6-8], and decreased satisfaction from the perspective of
the clinician [6]. In the complex and often frustrating
context of chronic disease management, approaches to
improve care are needed. An increasingly common ap-
proach towards this goal is patient engagement. Patient
engagement can occur at a variety of levels (for example,
encounter, organization, policy) and can vary in its in-
tensity [9]. Shared decision making (SDM) is an example
of an approach to patient engagement that occurs at the
level of the clinical encounter.
SDM is an approach to clinical encounters that desires
the intentional and cooperative involvement of both
patients and clinicians in the process of deliberation
about care. The goal of this approach is that clinicians
and patients will share their knowledge, values, and
preferences and deliberate together. Thus, SDM can
result in decisions that are more congruent with pa-
tient values, preferences, and context, which in turn
increase quality of life and improve the likelihood of
achieving health goals. SDM could improve clinical
outcomes when it leads to decisions patients are more
likely to implement and enact over time. SDM may
also play a role in improving clinician satisfaction in
the care of patients with chronic conditions through
facilitation of a stronger clinician-patient relationship
and a shared understanding of the treatment goals [10,11].
Multiple studies have shown that SDM interventions
can increase patient knowledge, reduce aspects of deci-
sional conflict, the proportion of patients remaining
undecided, and the proportion of patients who play a
passive role in the decision making process [12-15].
Primarily, these effects have been shown in studies of
decision aids. Decision aids are tools which can be
used to facilitate SDM and are defined by the Inter-
national Patient Decision Aids Standards (IPDAS) col-
laboration as:
‘tools designed to help people participate in decision
making about two or more health care options…(they)
provide information about the options and help
patients to clarify and communicate the personalvalues they associate with different features of the
options’ [16].
A diverse array of patient and clinician training pro-
grams has also been developed to implement SDM [17].
However, despite widespread policy interest [18,19] in
and research [12-15] around ways to implement SDM,
it is unclear what effect SDM has in the context of
chronic conditions. To date, no systematic reviews exist
on the effect of SDM on outcomes in patients with
chronic conditions.
SDM in chronic conditions is different from SDM in
acute settings or in the context of one-time decisions be-
cause of the ability to revisit and revise the decision. A
model of SDM in chronic conditions reflecting this has
been proposed [20]. We believe that despite this difference
(that is the ability to revisit and revise the decision), SDM
in chronic conditions should have similar effects as those
seen in systematic reviews that do not discriminate be-
tween SDM in chronic and non-chronic conditions (for
example, increase knowledge, reduce decisional conflict,
reduce proportion undecided, and reduce proportion of
patients playing a passive role in decision making); how-
ever, it is unknown whether this is the case.
To fill this gap, this study aims to determine the effective-
ness of SDM interventions compared to usual care or
alternative interventions (for example, patient education




We will conduct a systematic review adhering to the
reporting guidelines of the Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
statement [21].
Study registration
This systematic review is registered with PROSPERO
(registration number CRD42013005784; http://www.crd.
york.ac.uk/PROSPERO).
Criteria for considering studies for this review
Type of studies
We will include randomized controlled trials that compare
a SDM intervention to usual care, one or more alternative
interventions (for example, patient education or modified
intervention), or a combination of usual care and alterna-
tive intervention(s).
Type of participants
We will include studies involving patients with a diag-
nosis of one or more chronic conditions, as defined in
the US Department of Health and Human Services
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as ‘conditions that last a year or more and require on-
going medical attention and/or limit activities of daily
living’ (for example, diabetes, osteoarthritis, substance
abuse disorders) [22]. Study eligibility will not be restricted
based on age. Patients in eligible studies will need to be
facing an actual decision (that is studies will not be
eligible if the decision to be made is hypothetical, for
example, when patients are asked to make a choice
about a decision that will not actually be implemented)
and that decision must be able to revisited and revised.
In cases where the patient may not have agency to make
an informed decision (for example, young pediatrics/
seniors with advanced dementia), the caregiver will be
considered the decision maker.
Type of interventions
We will include studies that evaluate any intervention
aiming to improve SDM between clinicians and patients.
The concept of SDM has evolved over the past thirty
years, from a concept focused on informed consent [23]
to one focused on information exchange between clini-
cians and patients that encompasses not only the risks
and benefits of treatment options, but also the patient’s
and clinician’s values and preferences [24]. For this
review, we used a more current definition of SDM and
define a SDM intervention as any intervention that aims
to inform patients of the available options and their risks
and benefits, and engage patients in a decision making
process with their clinician.
Type of outcome measures
We will extract all reported outcomes from eligible studies,
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Figure 1 Shared decision making measurement framework.the measurement is subjective or objective in nature.
Outcomes will be classified using a novel measurement
framework (Figure 1). Any outcomes that do not fit
within this framework will be classified in an ‘other’ ca-
tegory. Outcomes will be included regardless of the time
of measurement.
Search methods for the identification of studies
We will design and conduct a search strategy using
methods recommended by the Institute of Medicine [25],
which includes a search of several databases including:
PubMed, Scopus, Ovid MEDLINE, Ovid EMBASE, Ovid
EBM Reviews CENTRAL, CINAHL, and Ovid PsycInfo. A
preliminary search strategy can be found in Additional
file 1. The databases will be searched from the time of
their inception to the current time. The initial electronic
search strategy will be supplemented by screening the ref-
erence lists from eligible included studies and through
contacting experts in the field to identify any missing,
in-progress or unpublished studies. In addition, we will
search for reviews on the topic and search through their
reference lists to identify any potentially eligible studies
that may have been missed through other methods. Fi-
nally, clinical trial registries will be searched to identify
completed and in-progress studies and, if not identified
through other methods, the authors will be contacted
for details regarding the study’s status. There will be no
language restrictions.
Selection of studies
We will upload search results into systematic review
software (DistillerSR, Ottawa, ON, Canada). In the first
round of screening, abstracts and titles will be screened
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abstract and full-text screening, reviewers will undergo
training to ensure a basic understanding of the back-
ground of the field and purpose of the review as well as
comprehension of the inclusion and exclusion criteria.
Eligibility at both levels (abstract and full-text) will be
assessed independently and in duplicate. At the title and
abstract screening level, both reviewers must be in
agreement in order to exclude an article; conflicts will
be included. At the level of full-text screening, any dis-
agreements will be resolved by consensus. If consensus
cannot be achieved between the two reviewers, a third
reviewer will arbitrate.
Data collection
In each study, we will extract: the outcomes, the time
when the outcomes were measured, the estimates of effect
for the outcomes and the error associated with those esti-
mates of effect. Furthermore, the instrument(s) used to
measure the outcomes in the studies (for example, Control
Preferences Scale for the outcome of preference for par-
ticipation decision making) will also be recorded. Other
items that will be extracted include: study year, location
(geographic and specialty/primary care) number of partici-
pating sites, number of participants in each arm of the
trial and average demographics (that is age, sex, race),
length of follow-up, losses to follow-up, condition(s) under
study, decision being made (that is what decision point is
being addressed using the SDM intervention), who deve-
loped the intervention (investigator versus pre-developed),
description of the intervention and control, theoretical or
conceptual underpinning for the study and intervention,
type of decision supported (decision to initiate, stop, in-
tensify, or de-intensify treatment), time of intervention
delivery (pre-visit/in-visit/post-visit, and so on), mode
of intervention delivery (paper/video/web/in-person, and
so on), and target of intervention (patient/clinician/
both/other).
Prior to data extraction from included studies, a data
extraction form will be created and pilot tested by the
data extractors on a subset of studies. The extraction
form will be changed based on feedback from the extrac-
tors to improve usability and ensure completeness. Data
extraction will be completed independently and in dupli-
cate. If disagreements arise, they will be resolved by con-
sensus. If a consensus cannot be reached between the two
parties, a third reviewer will arbitrate. If data presented in
the studies is unclear, missing, or presented in a form that
is either unextractable or difficult to reliably extract, the
authors of the study will be contacted for clarification.
When data extraction is complete, the authors of the stud-
ies will be contacted to ensure the accuracy and complete-
ness of the data extraction. In addition, at this time the
authors of included studies will be asked if they know ofany additional studies, either completed or ongoing, that
they believe would be eligible for our review.
Author contact will be initiated by an Email to the cor-
responding author. If an Email is unavailable, an Internet
search will be used to find a current Email address; when
Emails are available, first authors of manuscripts will be
carbon copied on all Emails to the corresponding author.
If Emails for the corresponding author are unavailable,
corresponding authors will be contacted by phone. Au-
thors will be given a week to respond to Emails, after
which time a follow-up Email will be sent; if no response
is received after an additional two weeks, a phone call will
be made to try to contact the author. Attempts to reach
authors by phone will occur throughout the week for a
period of two weeks at which time the author will be
classified as uncontactable.
Risk of bias assessment
We will use the Cochrane Collaboration’s risk of bias
tool to evaluate the methodological quality of included
studies [26]. The risk of bias in included studies will be
assessed in duplicate by reviewers working independently.
Any disagreements will be resolved by consensus, if con-
sensus is unable to be achieved, a third reviewer will arbi-
trate. Items included in the risk of bias assessment will
include: randomization, quality of randomization (any im-
portant imbalances at baseline), allocation concealment,
level(s) of blinding/masking, losses to follow-up, intention
to treat analysis, and funding sources. Reviewers will also
be given the option to leave full-text comments. Any free-
text comments left by the reviewers concerning the risk of
bias will also be taken under consideration in determining
the risk of bias of the study. This information will be used
to inform the interpretation of estimates of effect and may
be used as a way to stratify studies in sub-group analyses.
Risk of bias (high/low/unclear) will be determined for each
study based on the above mentioned factors. The first au-
thor along with another reviewer will determine overall
risk of bias using objective (number of items positive in
the risk of bias assessment) and subjective factors (the im-
portance of the presence or absence of said factors on the
studies risk of bias). If there are disagreements between
the two reviewers a third reviewer will arbitrate.
Analysis
We will first summarize and describe the populations,
interventions, and outcomes studied. Descriptive statistics
will be used as appropriate to compare the characteristics
of the studies and narratives will be used as necessary to
describe the interventions. Outcomes determined to be
similar based on a consensus of reviewers will be pooled.
Convenience samples of patients with chronic conditions,
clinicians, policy makers, and researchers, will be surveyed
and asked to rank the outcomes based on their perceived
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trials, we will stratify the trials based on condition studied.
Agreement at the level of screening and for the risk of bias
assessment will be measured using the kappa or phi statis-
tics, as appropriate (the latter is appropriate when the
distribution of agreement is extreme) [27].
Summary measures
We will use Review Manager version 5.2 for statistical
analysis [28]. We will use DerSimonian and Laird random-
effects models to calculate the relative risk (RR) with 95%
confidence intervals [29] for dichotomous variables and
weighted mean difference between groups for continuous
variables. For outcomes assessed using different measures,
we will report the standardized mean difference. A mini-
mum important difference will be defined as 0.5 standard
deviations [30]. We will report both random- and fixed-
effects models in the case of a discrepancy between them;
otherwise, we will report the random-effects model only.
Heterogeneity will be assessed using the I2 statistic and
values above 75% will be considered indicative of high
heterogeneity [31].
Missing data
If missing data exists within the included trials, we will
contact the authors to see if it is obtainable. If the data
is unobtainable, we will use the complete case analysis
and conduct sensitivity analysis for continuous outcomes
and dichotomous outcomes using the methods of Ebrahim
et al. [32] and Akl et al. [33], respectively.
Risk of bias across studies
Publication bias will be assessed by plotting the trial’s esti-
mate of effect by the inverse of its standard error using a
funnel plot. The plots will be assessed both visually and by
using Egger’s test; a significant publication bias will be
considered to exist if the P-value is < 0.1 [34].
Quality of evidence
For each outcome, tables summarizing the quality of the
evidence will be generated (that is evidence profiles and
summary of findings tables). These evidence summaries
will be generated based on guidance formulated by the
Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) Working Group [35].
Additional analyses
Following the primary analyses, several exploratory sub-
group analyses will be performed. The analyses will be
stratified by: 1) symptomatic conditions versus asympto-
matic conditions; 2) target of the intervention (patient/
clinician/both/other); 3) time of intervention delivery
(pre-consult/in-consult/post-consult); 4) children versus
adults; and 5) type of intervention (for example, trainingversus decision aid). We will also perform a sensitivity
analysis including and excluding information gleaned from
author contact.
Discussion
We anticipate that this systematic review will be useful
to a variety of stakeholders for several reasons. First, it
provides a broad, detailed overview of the field for re-
searchers and will highlight gaps where future research
on SDM and its implementation will need to be con-
ducted. Second, it will make available to clinicians know-
ledge related to the available SDM interventions and
their respective efficacies and limitations. Finally, the re-
view could potentially inform policy makers and funding
agencies by highlighting the state of the current body of
research, the efficacy of different SDM approaches, and
where future funding priorities should lie (for example,
novel SDM implementation strategy generation versus
comparative effectiveness research), which will be in-
formed by an innovative approach to ranking outcomes.
Evidence based medicine is most useful when it con-
siders and fulfills the needs of the end user of that evi-
dence. However, there are often many end users, each
with different needs, values, preferences, and contexts.
Therefore, to aid in the interpretation and presentation of
our review, we will conduct surveys of different end users
(patients, clinicians, researchers, and policy makers) to de-
termine which outcomes that have been measured are of
most importance to each end user and what, if any, out-
comes have not been measured (or have been measured
inconsistently) that are important to a specific group of
end users. We chose to use surveys over interviews or
focus groups because we wanted to generate the desired
information as efficiently as possible.
For this review, we propose a novel measurement
framework (Figure 1). This framework is tentative and
builds off of previous measurement frameworks [36-39].
It is anticipated that this framework will be modified based
on results of stakeholder feedback and of this review.
We anticipate that this systematic review will have
limitations such as significant heterogeneity and/or im-
precision for some of the outcomes and that this will
limit our confidence in the estimates of effect. As a re-
sult, we may find that for many outcomes, at this time,
we are unable to make any conclusions with a high degree
of confidence. An additional limitation is that historically,
there has been no ‘shared’ definition of what SDM is or
what constitutes a good or effective SDM interaction [24].
Thus, despite using a refined definition of SDM there may
still be significant conceptual heterogeneity which may
affect the interpretation of any results. Therefore, we
will conduct sensitivity analysis to explore the effect of
this heterogeneity. In addition, we will conduct sensitivity
analyses to explore the impact of information gathered
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handling missing data.
We believe this study will be an important contribution
to the field as it will highlight the effects interventions
aimed at improving the level of SDM have on a variety of
outcomes in the setting of chronic disease. We anticipate
this information will be useful to a variety of stakeholders
and that it will promote discussion both inside and outside
the field.
Additional file
Additional file 1: Search Strategy.
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